Ultrasonography plus radiography was as effective as intravenous urography for detecting abnormalities in men with proven urinary tract infection


QUESTION: What is the accuracy of ultrasonography plus abdominal radiography for detecting urinary tract abnormalities in men with proven urinary tract infection (UTI)?

Design
Blinded comparison of ultrasonography plus intravenous urography (IVU) (diagnostic standard).

Setting
The urology and nephrology departments of a district general hospital in Hertfordshire, England, UK.

Patients
114 consecutive men (mean age 54 y), with proven UTI. Complete data were obtained for 100 men.

Description of tests and diagnostic standard
Ultrasonography detected hydronephrosis in 8 patients, the test properties of ultrasonography plus radiography. Referral bias could be a concern because the study was done in a urology and nephrology referral centre. Other tests used in this study (eg, urine flow rate, cystoscopy, and transrectal ultrasonography) could play an important role in diagnosis, but they were not studied in a controlled fashion. The clinical bottom line is that there is no harm in starting with ultrasonography plus radiography when investigating the cause of UTI in men. A negative result can conclude the work-up, and a positive result can lead to further testing or a referral to a urology or nephrology unit.

Main outcome measures
Sensitivity, specificity, and likelihood ratios.

Main results
53 men had a detectable abnormality that was considered to be clinically significant. The table summarises the test properties of ultrasonography plus radiography. Both methods identified a pelvic kidney. Ultrasonography plus radiography identified 34 patients with a poorly emptying bladder, whereas IVU identified 26.

Conclusion
Ultrasonography plus radiography was as effective as intravenous urography for detecting clinically important abnormalities in men with proven urinary tract infection.

Test properties of ultrasonography plus radiography for detecting abnormalities in men with proven urinary tract infection*  

<table>
<thead>
<tr>
<th>Sensitivity (95% CI)</th>
<th>Specificity (CI)</th>
<th>LR⁻</th>
<th>LR⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td>100% (94 to 100)</td>
<td>93% (81 to 95)</td>
<td>14.67</td>
<td>0</td>
</tr>
</tbody>
</table>

*Diagnostic terms defined in glossary; CIs and LRs calculated from data in article.

COMMENTARY
UTIs in men are uncommon, and the diagnostic strategies to detect genitourinary abnormalities in these men are variable. The most common initial test is IVU, but a safer and less expensive alternative would be useful. In the study by Andrews et al, about 50% of the men had no abnormality detected on any of the diagnostic tests. The remaining participants had abnormal findings, such as excessive urine in the bladder after micturition, hydronephrosis, stones, renal scars, or a pelvic kidney. The performance properties of ultrasonography plus radiography are sufficiently close to IVU to make it a reasonable substitution. The authors suggest an algorithm that would have had the following results in this sample after ultrasonography plus radiography: 18% of patients would have been referred for IVU (abnormal findings in the upper tract), and 8% would have been referred for unnecessary work-up of lower urinary tract problems. However, this algorithm has not been evaluated in an independent population.

It is unclear which men with UTI need any evaluation, or when it should be done (ie, after the first infection or after subsequent infections). It would have been helpful to stratify the men by the number of previous UTIs and by age because one would expect the age range of 18 to 88 years to include men with very different probabilities of prostate hypertrophy. Referral bias could be a concern because the study was done in a urology and nephrology referral centre. Local differences in the cost and convenience of testing might make a difference in a cost-benefit analysis, although the risks associated with IVU are greater (about 4 times the ionising radiation and some risk from intravenous contrast). Sources of funding: no external funding.

For correspondence: Dr D Hanbury, Lister Hospital, Hertfordshire, UK. Email damian.hanbury@lister.nherts-tr.nhs.uk.